Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Corcept Therapeutics (CORT)

Corcept Stockholders Approve 8 Million Share Increase to Incentive Plan

Neutral Impact 2 of 5 shareholder Written later

At its May 21, 2026 annual meeting, Corcept Therapeutics stockholders approved an amendment adding 8,000,000 shares to the 2024 Incentive Award Plan, which took effect that day. The filing also reports the election of eight directors and the ratification of Ernst & Young LLP as the independent auditor for fiscal 2026. The plan increase expands the shares available for equity awards, which can dilute existing holders.

Key points

  • Stockholders approved the Amended 2024 Incentive Award Plan, adding 8,000,000 shares, with 53,163,364 votes for, 23,867,363 against and 263,730 abstaining.
  • All eight director nominees were elected to serve until the 2027 annual meeting, including Joseph K. Belanoff, M.D., and David L. Mahoney.
  • Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026, with 92,656,473 votes for.
  • In an advisory vote, stockholders approved named executive officer compensation, with 72,511,429 votes for and 4,560,385 against.

The filing

CompanyCorcept Therapeutics (CORT)
Form8-K, current report
Filed with the SECMay 28, 2026, 4:04 PM ET
Accession number0001628280-26-038793

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 28, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.